Detection and management of preclinical heart failure
Director, Menzies Research Institute Tasmania
Tom Marwick
Overt heart failure
(Stages C and D)
Risk factors including social
determinants and behaviour (Stage A)
Preclinical disease
Stage B
EARLY HEART FAILURE
Preclinical heart failure
Hunt SA, et al. J Am Coll Cardiol 2009;53:e1-e90
EARLY HEART FAILURE
HF stages
Stage BStructural heart
disease but without signs or symptoms of HF
Stage AAt high risk for HF without structural heart disease or
symptoms
Stage CStructural heart
disease with prior or current
symptoms of HF
Stage DRefractory HF
requiring specialized intervention
Patient with:-Previous MI-LV remodeling including LVH and low EF-Asymptomatic valvular disease
Patient with:-Hypertension-Atherosclerosis-Diabetes-Metabolic syndrome-Cardiotoxins-With FHx CM
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
4. Lessons about community-based RCTs
EARLY HEART FAILURE
TCF funding – Rural HF project
EARLY HEART FAILURE
What is heart failure?
Acute heart failure
Chronic heart failure
Australia (National Heart Foundation of Australia-HF guideline)
• Prevalence: 10% (> 65 yrs); 50% (> 85 yrs )
• Annual Incident HF: 30,000
• Annual admissions: 100,000
• Annual cost of care: $411 million (0.4% )
USA (Hunt SA ,2009)
• Prevalence: 5,800,000
• Incident rate: 500,000 /year
• Annual cost of care: 39 billion (1-2%)
Worldwide (McMurray JJ 1998)
• Prevalence: 23,000,000
EARLY HEART FAILURE
Magnitude of the Problem
EARLY HEART FAILURE
The heart failure epidemic
Hospital admissions per 1,000 population per year for heart failure (Kannel WG. Br Heart J 1994)
Why is HF increasing?- Aging- Survival from heart attack- Risk factors
- BP- diabetes- obesity
Chance of getting HF?- About 30%
HF IS THE SINGLE MOST EXPENSIVE DIAGNOSIS IN HEALTH SYSTEM
Wellcome Museum, London
EARLY HEART FAILURE
Metabolic drivers of the HF epidemic
EARLY HEART FAILURE
HF – Survival rate at 5 years
Stewart S, et al. More malignant than cancer? Five-year survival following a first admission for heart failure in Scotland. European Journal of Heart Failure 3 (2001) 315-322
Juenger J et al. Health related quality of life in patients with congestive heart failure: comparison with other chronic disease and relation to functional variables. Heart 2001; 87: 235
EARLY HEART FAILURE
Heart Failure - Quality of Life
Lynn J. JAMA 1997; 277:1633-40
PF: Physical functionRP: Role limitationBP: Body painGH: General health perceptionsVT: VitalitySF: Social functionRE: Emotional ProblemsMH: Mental Health
Focus on early disease to change trajectory
EARLY HEART FAILURE
HF is bad! What can we do about it?
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
4. Lessons about community-based RCTs
EARLY HEART FAILURE
TCF funding – Rural HF project
EARLY HEART FAILURE
Screening for HF
• Prevalence: 10% (> 65 yrs)
• At June 2010, there were 79,100 people aged 65 years and over in Tasmania - 15.6% of the population
• Can we afford to screen ~80,000 people in order to find ~8,000 with HF?
EARLY HEART FAILURE
What’s wrong with screening?
– The risk of false positive results • Lead to further unnecessary diagnostic testing, over-
treatment, some can be invasive
– Cause psychological distress and anxiety in asymptomatic people
– Need of evidence that screening and detection changes management outcomes
Screening for Heart Failure has not been recommended by the US Preventive Services Task Force
EARLY HEART FAILURE
Essentials of screening
Thomas Bayes, 1702-61
1. Choosing the right population
2. Having the right test
3. Absolute vs relative risk
4. Defining the phenotype
5. Having a treatment strategy
6. Knowing how to manage false positive and false negative tests
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
EARLY HEART FAILURE
Rural HF project
EARLY HEART FAILURE
Shrink the haystack
EARLY HEART FAILURE
Framingham HF Risk Score
EARLY HEART FAILURE
Health ABC HF Score
EARLY HEART FAILURE
ARIC HF Risk Score
EARLY HEART FAILURE
PRISMA- A Meta AnalysisTotal articles identified
(n=2947)
Articles reviewed by title or abstract(n=1974)
Articles included for meta-analysis (n=23)
Articles included in systematic review
(n=29)
18 additional articles from bibliographies included.
Articles for full text review (n=111)
Articles eligible for review(n=94)
Excluded duplicates(n=973)
Excluded by title or abstract (n=1880)
Excluded articles not reporting characteristics of
inclusion criteria(n=83)
Excluded articles reporting risk inconsistent with
inclusion criteria(n=6)
Inclusion:1)Study in
unselected population, community
2)Reporting risk effect size in RR/OR/HR
3)Outcome: incident heart failure
EARLY HEART FAILURE
Studies included
Author Study (Trial)Total(n)
F-U(year)
HF(n)
1Ho; Kannel ; Ho et al
Framingham study (Framingham and Offspring) 9450 40 652
2ButlerKalogeroul
Health ABC study (Health Aging and Body Composite Study)
2934 6.5 258
3 HeNHANES (National Health Nutrition Examination Survey
13643 19 1382
4 Eriksson Men born in 1913 (Sweden) 973 17 311
5 Agarwal ARIC (The Atherosclerosis Risk in Communities) 13555 15.5 1487
6 Goyal One Million Person-Year 359947 5 4001
7 Dunlay Population based CC-Mayo 1924 962
8 Bahrami MESA (Multi-Ethnic Study of Atherosclerosis) 6814 4 79
9Gottdiener; Mujib
Cardio Vascular Health 5625 12 597
10 Chen YTEPESE (Established Population for Epidemiologic Studies of the Elderly program)
1749 10 173
11 Wilhelmsen MPPS (Sweden) 7495 27 937
12 Bibbins-DCARDIA (Coronary Artery Risk Development in Young Adults)
5115 20 27
13 Ingelsson ULSAM 2321 29 259
14 Wang J Kuopio (Finland) 1032 20.7 303
15 Aronow Mt Sinai 2902 3.58 794
16 Smith JG MDCS (Sweden) 5187 14 112
17 Kenchaiah Physician’s heart (US) 21094 21 1109
18 Brouwers PREVEND (Netherlands) 8592 12 374
EARLY HEART FAILURE
Risk variables identified
Clinical Risks Clin Risks (uncontrollable)
Lab risk markers
Age Gender (male) Fasting Glucose
Obesity Smoking, COPD C-reactive protein
Diabetes Low Physical Activity Renal dysfunction
Family History Coffee, Alcohol Albumin
Hypertension Sleep disorder Dyslipidemia
Education, race Abnormal ECG (LVH)
Resting Heart Rate NT-proBNP, BNP
Atrial Fibrillation Troponin
Valvular Heart disease LVEF (echo, MRI)
Coronary artery disease (CAD)
BP medication
CVA or TIA Other medication
Risk Variable -
Hypertension
EARLY HEART FAILURE
Inclusion/ Exclusion
• > 65 years• Diabetes• High blood pressure /on
treatment• Overweight• Family history of heart failure • Past history of chemotherapy• Past history of heart disease• < 65 years
• > Moderate valve disease• History of heart failure• Already on BB and ACEi• Contraindications to BB or ACEi • Oncologic life expectancy <12
month• Inability to acquire adequate images
Inclusion
Exclusion
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
4. Lessons about community-based RCTs
EARLY HEART FAILURE
Rural HF project
myocyte
preproBNP (134 aa)
proBNP (108 aa) signal peptide (26 aa)
secretion
NT-proBNP (1-76) BNP (77-108)
EARLY HEART FAILURE
BNP release from Cardiac Myocytes
EARLY HEART FAILURE
BNP to ER presentation with dyspnea
Maisel A. J Am Coll Cardiol 2001
38+/-4141+/-31
1076+/-138
0
200
400
600
800
1000
1200
BN
P p
g/m
l
No CHF LV DysfunctionNo acute CHF
CHF
N=139 N=14 N=97
EARLY HEART FAILURE
Preclinical disease and BNP
n=101 apparently normal diabetic subjects (asymptomatic, normal EF)BNP in LVH pts was higher than those without LVH But only 4 had elevated BNP (using age and gender-specific normal ranges) - only 1 had low velocity/strainBNP is not a good marker of subclinical disease (no substitute for the echo lab!)
Fang ZY. Am Heart J 2005
0
500
1000
1500
2000
2500
Obese Non-obese
Ischemic Dilated
p<0.05
p<0.05
NT-proBNP (pg/ml)
Taylor A. Am Heart J 2006
EARLY HEART FAILURE
Echo is essential in HF diagnosis
SiemensSC2000
Philipsie33
GEVivid e9
EARLY HEART FAILURE
Progressive miniaturization
LA volume32ml/m2
EARLY HEART FAILURE
Early HF – Standard tests normal
EARLY HEART FAILURE
Measurement of strain
1.3 S-1
0.7 S-1
EARLY HEART FAILURE
Strain and sick heart muscle
EARLY HEART FAILURE
Other diagnostic markers?
• Central Blood Pressure• ECG • 6 Minute-walk Test (6MW)• Assessment of Activity and quality of life
– Minnesota MLHFQ score– Charlson comorbidity index– Duke Activity Status Index (DASI)– EQ5D – SOF frailty score
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
EARLY HEART FAILURE
Rural HF project
Stage B Heart failurecardio-protective Treatment
(SOLVD trial)
SOLVD – Prevention TrialStudy of Left Ventricular Dysfunction
percentage of event, defined as death or hospitalization for congestive Heart Failure, occurring in the placebo and Enalapril (ACEi) Groups
Cardio-protective Treatment of Stage B Heart failure (SAVE trial)
SAVE Trial - CaptoprilStudy of Survival and Ventricular Enlargement Trial
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
EARLY HEART FAILURE
Rural HF project
EARLY HEART FAILURE
Stage B HF - Progression to overt HF
• Natural history of SBHF
– Olmsted County study (n=1760)
– LV dysfunction in T2DM– 25% HF in 2 years,
36.9% in 5 years, twice the rate of HF in patients without LV dysfunction
Aaron M. From et al. The development of Heart Failure in Patients with Diabetes Mellitus and Preclinical Diastolic Dysfunction: A Population Based Study. JACC 2010 26; 55(4)
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
EARLY HEART FAILURE
Rural HF project
“55113 – Cardiac M-mode and 2 dimensional real time echocardiographic examination of the heart … for the investigation of symptoms or signs of cardiac failure, or suspected or known ventricular hypertrophy or dysfunction, or chest pain”
DHHSTHOs
Tasmania Medicare Local
Medicare
EARLY HEART FAILURE
Changes needed
EARLY HEART FAILURE
Research Questions
1. What is the prevalence of Stage B Heart Failure (LVSD & LVDD) in at risk population in Tasmanian community
2. How does functional capacity (6MW test) correlates with echo systolic and diastolic parameters
3. How does central blood pressure associate with diastolic dysfunction and LV mass
4. What is a better echo marker LVEF, GLS and diastology in stage B heart failure.
5. How does screening and early treatment affect quality of life?
6. Is community screening cost effective?
7. What are the main constrains of a community screening model? Main constrains of treatment delivery.
TASELF - Study design
Title Tasmanian Study of Echocardiographic detection of Left ventricular dysfunction
Trial acronym TAS-ELF (H00013333)
Trial ID ACTRN12614000080628
Study Type Interventional (Prospective Randomized Open Blinded Endpoint-Probe)
Allocation Randomized Controlled (Adaptive)
Sample size 400 x 400 (=0.044, β=0.8; 7.8% annual loss); 25% versus 12.5% in 2 yrs
Random seq. Masking/blind
Enrollment followed by randomization (central web-based program).Masked: those involved in recruiting, randomization, analyzing data.
Participants Eligibility: (>65 year, Stage A[ACC/AHA guideline]); Exclusion: BB + ACEi
Recruitment 18 months. Self-referred (by advertising and recommendation by GP)
Follow Up Phone tracking on 1st, 6th,12th,18th,24th month. Repeat assessment: 24th month.
PrimarySecondary
New onset of heart failure; 6 minutes walk test distance
TASELF Planned sites
HobartHuonvilleOatlands GeevestonLongfordDeloraine LauncestonSmithton Ulverstone George Town DevonportNew NorfolkSorrellKingstonScottdaleQueenstownSt Helen’s
EARLY HEART FAILURE
How we will screen for HF
EARLY HEART FAILURE
Planned protocol
Apparently healthy subject with HF risk
Exclusion of known HF, co-morbidities, CAD
Subclinical LVD – start ACEi and BB(n=120)
Normal LV
2 y
ear
follo
w-u
p f
or
HF
and f
unct
ional ca
paci
ty
Clinically suitable for randomization
Clinical questionnaires Usual
care
Exclusion of reduced EF (<40%), valve disease, CADBNP in borderline
Baseline echo
Randomize1:1 (n=800) Echo strain,
diastology
HF 25%
HF 10%
HF 5%
Aim to study 800 subjects in the 1st year (400 subjects with HF screening and therapy vs 400 controls)~16 studies per week (ie 2 trips/week)
TASELF Registry – updated May 2014
Assessed for eligibility
(n=511)
Randomized
(n=220)
Allocation
Allocated to intervention (=104)
- Treatment (n=76)
- Observation (Normal echo) (n=28)
Allocated to observation (n=116)
- Treatment (n=2)
- Observation (n=114)
Excluded (n=178)
Not meeting inclusion
Participant registered (n=828)
• At June 2010, there were 79,100 people aged 65 years and over in Tasmania - 15.6% of the population
• The prevalence of people in this age group with diabetes (T2DM), obesity, high blood pressure, past cancer therapy or known cardiac disease is about 50% - roughly 40,000 people (100 times the number in the study)
• An effective program on a state-wide basis would avoid/delay heart failure in 2,400 people.
EARLY HEART FAILURE
The Big Picture
Stakeholder Impact of project on stakeholdersProf Marwick and Ms Yang Support of their research activitiesMenzies Research Institute Tasmania
Leadership of a community-based initiative that aligns with the mission of the Institute
Rural GPs Access to diagnostic testing that may help identify and avoid patients developing a potential problem with heart failure
Rural communities Access to a service that will reduce the risk of serious illness and hospital admission far away from their family/social support
Consultants/hospitals Reduction of urgent heart failure admissions
Wider community If successful, the proposed strategy will be of value in all practices and not restricted to the rural community
EARLY HEART FAILURE
Stakeholders
Item Amount Source
Contribution to Echo equipment $150,000 Tas Community Fund
Contribution to Echo equipment $105,000 Siemens
Sonographer PhD scholarship $75,000 National Heart Foundation
Supervision – Principal investigator, cardiologists, GPs
$50,000+ Menzies, THO-S, practices
Support of travel, research assistants $50,000$40,000
Diabetes AustraliavTAHSP
Total ~$500k
EARLY HEART FAILURE
Support
Thank you
1. Why - The epidemiology of heart failure
2. Detection - is HF screening an option?a. Right population
b. Right test
c. Rx strategy
d. Measuring outcomes
e. Quantifying risk, FP and FN results
3. Proof of Principle – TasELF study
4. Lessons about community-based RCTs
EARLY HEART FAILURE
Rural HF project
EARLY HEART FAILURE
Time frame
Tasks Responsible person Start date Due date Milestones
Communication with GPs, advertising to communities
Prof Tom Marwick, Dr Michael Lees
1st July 2013 30th June 2014 Recruitment of ~10 communities
Ethics application Prof Tom Marwick 1st July 2013 17th July 2014 Approval
Screening and imaging in communities
Ms Hilda Yang, other members of Prof Tom Marwick’s team
1st July 2013 30th June 2014 Screening of 800 subjects in 12 months
Treatment of patients with undiagnosed disease
Dr Michael Lees, GPs in other communities, supported by Dr Jeff Evans, Prof Marwick, RHH and LGH cardiologists
1st July 2013 30th July 2016 Appropriate management of identified patients
Follow-up at 12, 24, 36 months
Ms Hilda Yang, other members of Prof Tom Marwick’s team
1st July 2014 30th June 2016 Follow-up of screened subjects
Data analysis Prof Tom Marwick, Hilda Yang
1st July 2016 30th July 2016 Complete analysis
Dissemination of results Prof Tom Marwick, Hilda Yang
30th July 2016 December 2016 Submission to Australian and international symposia and publication
Translation of science to practice
Prof Tom Marwick 30th July 2016 December 2016 Implementation of screening programme Statewide
Risk Likelihood Seriousness Mitigation plan
Failure to recruit practices in other towns
Low Serious Contacts already being made
Failure to recruit appropriate patients
Low Serious Direct approaches to communities
Loss of patients to follow-up Low Serious Direct approaches to communities
Less then expectedincidence of eligible pts fitting screening criteria
Low Moderate Increase recruitment
Less incidence of early stage HF than expected
Low Low Very unlikely - that would be an excellent outcome!
Lower success than anticipated in reducing % that develop late stage HF
Low Low None – this would be a negative study. The community still have the benefit of vascular screening.
Lack of buy-in from Government Agencies to implement programme
Moderate if the effect is less than anticipated
Serious Involvement of the Heart Foundation and Diabetes Australia to help make our case with government.
HEART FAILURE IN RURAL COMMUNITIES
Risk evaluation
1,760 diabetic pts with assessment of cardiac function; 411 (23%) abnormalEvery 1-U increase in E/e' ratio a/w increase of HF hazard ratio of 3%Diastolic dysfunction a/w HF after adjustment for age, sex, BMI, HT, CAD and echo parameters (HR: 1.61; p = 0.003).
From AM et al. J Am Coll Cardiol 2010
EARLY HEART FAILURE
Implications of Early HF